Zolgensma didn't cause an infant death, AveXis execs say as they spotlight long-term data
Before the recent data manipulation scandal engulfed Novartis’ star gene therapy Zolgensma, the death of an infant in one of their Phase III trials …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
